Nephro-Urology Monthly

Published by: Kowsar

Comparison of Azithromycin and Clarithromycin Triple Therapy Regimens for Helicobacter Pylori Eradication in hemodialysis Patients

Mojgan Jalalzadeh 1 , Morteza Nazarian 2 , Jamshid Vafaeimanesh 3 , * and Fatemeh Mirzamohammadi 4
Authors Information
1 Departments of Nephrology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Departments of Gastroetrology, Vali-e-asr Hospital, Zanjan University of Medical Sciences, Zanjan, IR Iran
3 Departments of Internal Medicine, Qom University of Medical Sciences, Qom, IR Iran
4 Student Research Committee, Vali-e-asr Hospital, Zanjan University of Medical Sciences, Zanjan, IR Iran
Article information
  • Nephro-Urology Monthly: June 01, 2012, 4 (3); 571-577
  • Published Online: June 20, 2012
  • Article Type: Research Article
  • Received: October 12, 2011
  • Revised: November 17, 2011
  • Accepted: November 27, 2011
  • DOI: 10.5812/numonthly.2794

To Cite: Jalalzadeh M, Nazarian M, Vafaeimanesh J, Mirzamohammadi F. Comparison of Azithromycin and Clarithromycin Triple Therapy Regimens for Helicobacter Pylori Eradication in hemodialysis Patients, Nephro-Urol Mon. 2012 ; 4(3):571-577. doi: 10.5812/numonthly.2794.

Abstract
Copyright © 2012, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Yildiz A, Besisik F, Akkaya V, Sever MS, Bozfakioglu S, Yilmaz G, et al. Helicobacter pylori antibodies in hemodialysis patients and renal transplant recipients. Clin Transplant. 1999; 13(1 Pt 1): 13-6[DOI][PubMed]
  • 2. Fauci A, Kasper D, Hauser S, Longo D, Jameson J, Loscalzo J. Harrison’s Principles of Internal Medicine 18/e. 2011;
  • 3. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ, Jr., Saeed ZA, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med. 1992; 116(9): 705-8[PubMed]
  • 4. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, et al. Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002; 16(2): 167-80[DOI][PubMed]
  • 5. Karari EM, Lule GN, McLigeyo SO, Amayo EO. Endoscopic findings and the prevalence of Helicobacter pylori in chronic renal failure patients with dyspepsia. East Afr Med J. 2000; 77(8): 406-9[PubMed]
  • 6. T. Daugirdas J, Gerard Blake P, S. Ing T. Handbook of dialysis. 2006;
  • 7. Nakajima F, Sakaguchi M, Amemoto K, Oka H, Kubo M, Shibahara N, et al. Helicobacter pylori in patients receiving long-term dialysis. Am J Nephrol. 2002; 22(5-6): 468-72[DOI][PubMed]
  • 8. Ala-Kaila K. Upper gastrointestinal findings in chronic renal failure. Scand J Gastroenterol. 1987; 22(3): 372-6[DOI][PubMed]
  • 9. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol. 1998; 93(12): 2330-8[DOI][PubMed]
  • 10. Sullivan B, Coyle W, Nemec R, Dunteman T. Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. Am J Gastroenterol. 2002; 97(10): 2536-9[DOI][PubMed]
  • 11. Gumurdulu Y, Serin E, Ozer B, Kayaselcuk F, Ozsahin K, Cosar AM, et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. World J Gastroenterol. 2004; 10(5): 668-71[PubMed]
  • 12. Altintas E, Sezgin O, Ulu O, Aydin O, Camdeviren H. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol. 2004; 10(11): 1656-8[PubMed]
  • 13. Osato MS, Reddy R, Graham DY. Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. Int J Antimicrob Agents. 1999; 12(4): 341-7[DOI][PubMed]
  • 14. Ellenrieder V, Boeck W, Richter C, Marre R, Adler G, Glasbrenner B. Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication. Scand J Gastroenterol. 1999; 34(8): 750-6[DOI][PubMed]
  • 15. Alarcon T, Domingo D, Lopez-Brea M. Antibiotic resistance problems with Helicobacter pylori. Int J Antimicrob Agents. 1999; 12(1): 19-26[DOI][PubMed]
  • 16. Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, et al. Helicobacter pylori in developing countries. WGO Global Guideline. 2010;
  • 17. Blandizzi C, Malizia T, Gherardi G, Costa F, Marchi S, Marveggio C, et al. Gastric mucosal distribution and clinical efficacy of azithromycin in patients with Helicobacter pylori related gastritis. J Antimicrob Chemother. 1998; 42(1): 75-82[DOI][PubMed]
  • 18. Trevisani L, Sartori S, Galvani F, Ruina M, Caselli M, Verdianelli G, et al. Evaluation of a new ultrashort triple therapy for Helicobacter pylori disease. Aliment Pharmacol Ther. 1998; 12(12): 1269-72[DOI][PubMed]
  • 19. Vcev A, Stimac D, Vceva A, Takac B, Pezerovic D, Ivandic A. High dose omeprazole plus amoxicillin and azithromycin in eradication of Helicobacter pylori in duodenal ulcers. Helicobacter. 1999; 4(1): 54-7[DOI][PubMed]
  • 20. Lieber CS, Lefevre A. Ammonia as a source of gastric hypoacidity in patients with uremia. J Clin Invest. 1959; 38(8): 1271-7[DOI][PubMed]
  • 21. Tsujii M, Kawano S, Tsuji S, Fusamoto H, Kamada T, Sato N. Mechanism of gastric mucosal damage induced by ammonia. Gastroenterology. 1992; 102(6): 1881-8[PubMed]
  • 22. Khedmat H, Ahmadzad-Asl M, Amini M, Lessan-Pezeshki M, Einollahi B, Pourfarziani V, et al. Gastro-duodenal lesions and Helicobacter pylori infection in uremic patients and renal transplant recipients. Transplant Proc. 2007; 39(4): 1003-7[DOI][PubMed]
  • 23. Sugimoto M, Sakai K, Kita M, Imanishi J, Yamaoka Y. Prevalence of Helicobacter pylori infection in long-term hemodialysis patients. Kidney Int. 2009; 75(1): 96-103[DOI][PubMed]
  • 24. Tsukada K, Miyazaki T, Katoh H, Yoshikawa M, Masuda N, Ojima H, et al. Helicobacter pylori infection in hemodialysis patients. Hepatogastroenterology. 2003; 50(54): 2255-8[PubMed]
  • 25. Huang JJ, Huang CJ, Ruaan MK, Chen KW, Yen TS, Sheu BS. Diagnostic efficacy of (13)C-urea breath test for Helicobacter pylori infection in hemodialysis patients. Am J Kidney Dis. 2000; 36(1): 124-9[DOI][PubMed]
  • 26. al-Assi MT, Genta RM, Karttunen TJ, Cole RA, Graham DY. Azithromycin triple therapy for Helicobacter pylori infection: azithromycin, tetracycline, and bismuth. Am J Gastroenterol. 1995; 90(3): 403-5[PubMed]
  • 27. Laurent J, Megraud F, Flejou JF, Caekaert A, Barthelemy P. A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther. 2001; 15(11): 1787-93[DOI][PubMed]
  • 28. Krichhoff RM, Laufen H, Schacke G, Kirchhoff G, Gallo E. Determination of azithromycin in gastric biopsy samples. Int J Clin Pharmacol Ther. 1999; 37(7): 361-4[PubMed]
  • 29. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001; 345(11): 784-9[DOI][PubMed]
  • 30. Silva FM, Eisig JN, Teixeira AC, Barbuti RC, Navarro-Rodriguez T, Mattar R. Short-term triple therapy with azithromycin for Helicobacter pylori eradication: low cost, high compliance, but low efficacy. BMC Gastroenterol. 2008; 8: 20[DOI][PubMed]
  • 31. Vcev A, Stimac D, Ivandic A, Vceva A, Takac B, Pezerovic D. Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer. Aliment Pharmacol Ther. 2000; 14(1): 69-72[DOI][PubMed]
  • 32. Sung JJ, Sanderson JE. Hyperhomocysteinaemia, Helicobacter pylori, and coronary heart disease. Heart. 1996; 76(4): 305-7[DOI][PubMed]
  • 33. Furuta T, Shirai N, Xiao F, Takashima M, Hanai H. Effect of Helicobacter pylori infection and its eradication on nutrition. Aliment Pharmacol Ther. 2002; 16(4): 799-806[DOI][PubMed]
  • 34. Nardone G, Rocco A, Fiorillo M, Del Pezzo M, Autiero G, Cuomo R, et al. Gastroduodenal lesions and Helicobacter pylori infection in dyspeptic patients with and without chronic renal failure. Helicobacter. 2005; 10(1): 53-8[DOI][PubMed]
  • 35. Wiesholzer M, Harm F, Schuster K, Putz D, Neuhauser C, Fiedler F, et al. Initial body mass indexes have contrary effects on change in body weight and mortality of patients on maintenance hemodialysis treatment. J Ren Nutr. 2003; 13(3): 174-85[DOI][PubMed]
  • 36. Baradaran A, Nasri H. Association of Helicobacter pylori IgG antibody with various demographic and biochemical parameters in kidney transplant recipients. Saudi J Kidney Dis Transpl. 2011; 22(6): 1115-20[PubMed]
  • 37. Sezer S, Ibis A, Ozdemir BH, Ozdemir FN, Kulah E, Boyacioglu S, et al. Association of helicobacter pylori infection with nutritional status in hemodialysis patients. Transplant Proc. 2004; 36(1): 47-9[DOI][PubMed]
  • 38. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, et al. Helicobacter pylori eradication has no effect on metabolic and inflammatory parameters. J Natl Med Assoc. 2005; 97(4): 508-13[PubMed]
  • 39. Medicinnet.com.Pharmacy Author : Omudhome Ogbru, PharmD.
  • 40. Ball P. The future role and importance of macrolides. J Hosp Infect. 1991; 19: 47-59[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments